Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
4 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Fatty liver disease (NASH/MASH)💵 May compensate
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Obesity / overweight💵 May compensate
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Testing a diabetes drug in people with fatty liver and excess weight
📍 Arizona Clinical Trials · Chandler, AZ · +22 more US sites · Get directions →
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
- Obesity / overweight💵 May compensate
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Testing tirzepatide to treat obesity in people with atrial fibrillation
📍 Cleveland Clinic · Cleveland, OH · Get directions →
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo.
- Type 2 diabetes💵 May compensate
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Testing how semaglutide affects blood sugar and weight in people with spinal cord injury and type 2
📍 University Health - Texas Diabetic Institute · San Antonio, TX · +1 more US site · Get directions →
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.